Breathgreen Pharmaceuticals

Breathgreen is a South Korean biotechnology company dedicated to developing advanced inhalation therapies for respiratory disorders. The company utilizes a proprietary dry powder inhaler (DPI) technology platform designed to enhance drug delivery efficiency and therapeutic outcomes for patients with chronic obstructive pulmonary disease (COPD) and asthma. By focusing on optimized lung deposition and user-friendly device design, Breathgreen aims to address unmet needs in the global respiratory market. Their pipeline features combination therapies and reformulated small molecules tailored for pulmonary administration. The company's lead programs are currently in the pre-clinical stages, focusing on high-stability formulations that do not require cold chain storage.